This seems (as in the following) to be much different than we have been told to date as to how the clinical trial will be conducted. 

"Apr 16, 2021 - ) An Open-Label Study to Assess the Safety and Effect on Clinical Course and Key Biomarkers of Oral Apabetalone in Hospitalized Subjects with COVID-19 Infection in Addition to Standard of Care (SOC) RVX000222 (Apabetalone) Resverlogix Corp 2021-04-06 N/A CORE-COVID (Control # 249936) A Randomized Clinical Trial Comparing 7 Days Treatment with Corticosteroids"

We have been told the following concerning the clinical trial:

"Study participants will either receive twice daily doses of apabetalone for up to 4 weeks alongside standard of care or, alternatively, standard of care without apabetalone. "

Will Resverlogix be conducting two separate trials?

Koo